Skip to main content

Month: August 2023

Alamos Gold Files Technical Report for the Lynn Lake Project

TORONTO, Aug. 22, 2023 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today announced that it has filed a technical report for its Lynn Lake project, located in Manitoba, Canada. The report was prepared in accordance with National Instrument 43-101 – Standards for Disclosure for Mineral Projects and supports the disclosure outlined in Alamos’ news release dated August 2, 2023. The report is available on the Alamos website at www.alamosgold.com and will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca. About Alamos Alamos is a Canadian-based intermediate gold producer with diversified production from three operating mines in North America. This includes the Young-Davidson and Island Gold mines in northern Ontario, Canada and the Mulatos mine in Sonora State, Mexico. Additionally,...

Continue reading

Helium Evolution Announces Filing of Second Quarter 2023 Financial Results and Provides Operations Update

CALGARY, Alberta, Aug. 22, 2023 (GLOBE NEWSWIRE) — Helium Evolution Incorporated (TSXV:HEVI) (“HEVI” or the “Company“), a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, today announced the filing of the Company’s interim condensed financial statements and associated management’s discussion and analysis for the three and six month periods ended June 30, 2023 (the “Quarterly Report”). Complete details of the Quarterly Report are available on SEDAR at www.sedar.com, and on HEVI’s website. Three and Six Month Periods Ended June 30, 2023 Highlights:  Three months ended Six months endedTabular amounts in thousands ofCanadian Dollars, except share and per share amounts June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022Financial        Net loss 331 1,342 642 2,996Net...

Continue reading

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in distribution More than 100,000 vials have been distributed/administered between real world and clinical trials; since last update, confirmed one additional event of retinal vasculitis that occurred in MayWALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare events of retinal vasculitis reported in real-world treatment with SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Recommended use of filter needles included in certain...

Continue reading

Paycor to Present at Upcoming Investor Conferences

CINCINNATI, Aug. 22, 2023 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (HCM) software, today announced that management is scheduled to present at the following investor conferences.Stifel Tech Executive Summit in Deer Valley, UT on Tuesday, August 29, 2023 at 8:30 am Mountain Time Citi Global Technology Conference in New York, NY on Wednesday, September 6, 2023 at 8:15 am Eastern Time Goldman Sachs Communacopia and Technology Conference in San Francisco, CA on Thursday, September 7, 2023 at 9:30 am Pacific TimeWhere available, webcasts of the events will be available live and accessible for replay for a limited time under the “Events & Presentations” section of Paycor’s investor relations website at https://investors.paycor.com/. About Paycor Paycor’s...

Continue reading

Associated Capital Group Sets Record Date for 2023 Shareholder Designated Charitable Contribution

GREENWICH, Conn., Aug. 22, 2023 (GLOBE NEWSWIRE) — Associated Capital Group, Inc. (NYSE: AC) has set October 15, 2023 as the record date for its 2023 Shareholder Designated Charitable Contribution (“SDCC”). AC previously announced the approval of a $0.20 per share SDCC for all registered Class A and Class B shareholders. To be eligible, shareholders will have until October 15, 2023 to register shares directly with Computershare, AC’s transfer agent. Shareholders can then designate a 501(c)(3) charitable organization to receive the $0.20 per share SDCC. Based on the 21.7 million shares currently outstanding, AC’s total contribution will be approximately $4.3 million. In late October, AC will provide forms to registered holders to designate recognized 501(c)(3) charitable organizations. There will also be an option to designate charitable...

Continue reading

La-Z-Boy Reports First Quarter Fiscal 2024 Results

Company owned Retail written same-store sales increased 2% Delivered sales and operating margin in line with guidance GAAP diluted EPS of $0.63; Non-GAAP diluted EPS of $0.62 Resumed share buybacks in the quarter with $10 million in share repurchases Second quarter guidance for sales of $490-$510 million and operating margin of 6.5%-7.5%MONROE, Mich., Aug. 22, 2023 (GLOBE NEWSWIRE) — La-Z-Boy Incorporated (NYSE: LZB), a global leader in the manufacture and retail of residential furniture, today reported first quarter results for the period ended July 29, 2023. Sales totaled $482 million, in line with guidance of $470 to $490 million, and a decrease of 20% against a year ago period that benefited from delivery of pandemic related backlog. Company owned Retail written same-store sales for the first quarter increased 2% versus...

Continue reading

BioSyent Releases Q2 and H1 2023 Financial Results

MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023. Key highlights include:  Second quarter (Q2) 2023 Total Company Net Revenues of $7,962,800 increased by 20% versus Q2 2022 First half (H1) 2023 Total Company Net Revenues of $14,445,494 increased by 6% versus H1 2022 Record Q2 2023 Canadian Pharmaceutical Net Revenues of $7,721,746 increased by 23% versus Q2 2022 H1 2023 Canadian Pharmaceutical Net Revenues of $14,133,440 increased by 12% versus H1 2022 Q2 2023 International Pharmaceutical Net Revenues were $nil as compared to $nil for Q2 2022 H1 2023 International Pharmaceutical Net Revenues were $nil as compared to $565,787 for H1 2022 Q2 2023 EBITDA1 of $1,859,931 increased by 10% versus Q2...

Continue reading

Complete Solaria Reports Second Quarter 2023 Results

Revenue Segment Performance by Quarter ($ millions)Revenue Segment Performance by Quarter ($ millions)FREMONT, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) — Complete Solaria Inc. (NASDAQ: CSLR) published its second quarter 2023 results, which will be reviewed for investors at 5:00 p.m. EDT today, https://investors.completesolaria.com/. Second quarter summary (financial comments based on non-GAAP results unless noted):Revenue of $32.2 million, down 9% from previous quarter Systems: $25.6 million, up 54% QoQ, and a recordModules: $6.6 million, down 65% QoQ18% gross margin, up 6% QoQ Strategic Decision: company to pursue only higher-margin Systems business in the future Sale of Modules business: non-binding term sheet with module manufacturer signed Streamlined organization: RIF of 59 with $7.9 million of annualized savings New...

Continue reading

Toughbuilt Industries Announces Second Quarter 2023 Results

Revenue increased 5.5% year-over-year to $18.9 million Gross profit increased 18.5% year-over-year to $5.8 million Gross Margin increased by 330 basis points year-over-year to 31% Net loss improved 53% year-over-year down to $5.9 million from $12.1 million IRVINE, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt” or “the Company”) (NASDAQ: TBLT; TBLTW), reported today their financial results for the fiscal quarter ended June 30, 2023. The Company will host its Q2 2023 earnings conference call today at 5:00 p.m. (ET). Financial Highlights for the Quarter Ended June 30, 2023 include:Revenues increased by approximately 5.5% to $18.9 million for Q2 2023, compared to $17.9 million in Q2 2022. This increase was primarily due to wide acceptance of the Company’s products and recurring sales...

Continue reading

URBN Reports Record Q2 Sales

PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) — Urban Outfitters, Inc. (NASDAQ:URBN), a leading lifestyle products and services company which operates a portfolio of global consumer brands comprised of the Anthropologie Group (Anthropologie and Terrain), Free People Group (Free People and FP Movement), Urban Outfitters, Nuuly and Menus & Venues brands, today announced net income of $104.1 million and earnings per diluted share of $1.10 for the three months ended July 31, 2023. For the six months ended July 31, 2023, net income was $156.9 million and earnings per diluted share were $1.67. Total Company net sales for the three months ended July 31, 2023, increased 7.5% to a record $1.27 billion. Total Retail segment net sales increased 5.9%, with comparable Retail segment net sales increasing 4.9%. The increase in Retail segment...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.